This course aims to provide a summary of the 2022 updates to the National Institute for Health and Care Excellence (NICE) guidelines on the management of people with type 2 diabetes. It will consider the change in emphasis from a target-driven and gluco-centric approach towards a greater focus on cardio-renal risk reduction. This shift in focus places the assessment of current and future cardiovascular risk at the centre of treatment. We will consider the opportunities this brings to offer our patients a more personalised approach to pharmacological treatment of diabetes in primary care, including the need to avoid intensive treatment in frailer patients.
This series of medical education events is sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of faculty. Editorial and content decisions were made solely by the RCGP and faculty chosen by RCGP.
